The impact of the COVID-19 pandemic on cancer diagnosis and service access in New Zealand–a country pursuing COVID-19 elimination

The Lancet Regional Health. Western Pacific

Alex Dunn¹  Elinor Millar²  Nina Scott³  Myra Ruka⁴  Richard North⁵  Jason K. Gurney⁶  Claire Hardie⁶  Chris G.C.A. Jackson⁶  Ruth Pirie⁶  Michelle Mako⁶  John Manderson⁶  Diana Sarfati⁷ 

[1] Corresponding author at: Department of Public Health, University of Otago, Mein St, Wellington, New Zealand.;Department of Public Health, University of Otago, Mein St, Wellington, New Zealand;Bay of Plenty District Health Board, Cameron Rd, Tauranga, New Zealand;Department of Medicine, University of Otago, Great King St, Dunedin, New Zealand;Midcentral District Health Board, Ruahine Street, Palmerston North, New Zealand;Te Aho o Te Kahu – Cancer Control Agency, Molesworth St, Wellington, New Zealand;Waikato District Health Board, Pembroke Street, Hamilton, New Zealand;

关键词: COVID-19;    COVID;    Coronavirus;    Cancer;    Cancer services;    Cancer registration;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: The COVID-19 pandemic has disrupted cancer services globally. New Zealand has pursued an elimination strategy to COVID-19, reducing (but not eliminating) this disruption. Early in the pandemic, our national Cancer Control Agency (Te Aho o Te Kahu) began monitoring and reporting on service access to inform national and regional decision-making. In this manuscript we use high-quality, national-level data to describe changes in cancer registrations, diagnosis and treatment over the course of New Zealand's response to COVID-19. Methods: Data were sourced (2018–2020) from national collections, including cancer registrations, inpatient hospitalisations and outpatient events. Cancer registrations, diagnostic testing (gastrointestinal endoscopy), surgery (colorectal, lung and prostate surgeries), medical oncology access (first specialist appointments [FSAs] and intravenous chemotherapy attendances) and radiation oncology access (FSAs and megavoltage attendances) were extracted. Descriptive analyses of count data were performed, stratified by ethnicity (Indigenous Māori, Pacific Island, non-Māori/non-Pacific). Findings: Compared to 2018–2019, there was a 40% decline in cancer registrations during New Zealand's national shutdown in March-April 2020, increasing back to pre-shutdown levels over subsequent months. While there was a sharp decline in endoscopies, pre-shutdown volumes were achieved again by August. The impact on cancer surgery and medical oncology has been minimal, but there has been an 8% year-to-date decrease in radiation therapy attendances. With the exception of lung cancer, there is no evidence that existing inequities in service access between ethnic groups have been exacerbated by COVID-19. Interpretation: The impact of COVID-19 on cancer care in New Zealand has been largely mitigated. The New Zealand experience may provide other agencies or organisations with a sense of the impact of the COVID-19 pandemic on cancer services within a country that has actively pursued elimination of COVID-19. Funding: Data were provided by New Zealand's Ministry of Health, and analyses completed by Te Aho o Te Kahu staff.

【 授权许可】

Unknown